Literature DB >> 27569051

Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction.

Irina Zvereva1, Ekaterina Semenistaya2, Grigory Krotov2, Grigory Rodchenkov2.   

Abstract

Small peptides with a molecular weight of <2kDa represent a performance-enhancing substances. However, in vivo studies with human volunteers are limited because most of these peptides are not approved for human consumption. Thus, relevant in vitro models are a basic tool to study their metabolism for anti-doping purposes. To choose the best in vitro model the biotransformation of growth hormone releasing peptides (GHRPs), Desmopressin and TB-500 was investigated using various in vitro systems. High metabolic activity was observed during incubation of GHRPs and TB-500 with human kidney microsomes (HKM) and liver S9 fraction. Peptides degraded through cleavage of all bonds regardless protective modifications in primary structure. HKM and liver S9 fraction demonstrated enzymatic deamidation activity removing C-terminal amide group from all GHRPs. Fewer metabolites were produced during incubation with human serum. The metabolite pattern obtained with commercially available proteases was poor and included nonspecific hydrolyzed compounds. Thus, the maximum diversity of metabolites was achieved with HKM and liver S9 fraction which makes them the most efficient in vitro model systems for peptides biotransformation study. BIOLOGICAL SIGNIFICANCE: Currently, >60 peptide medicines are FDA approved and marketed in the United States as biopharmaceutical products. Approximately 140 peptide drugs are in clinical trials and about 500 therapeutic peptides in preclinical development. There is an emerging interest in small peptides with a molecular weight of <2kDa, which can be used as doping in modern sport due a wide spectrum of their physiological activity. Most of peptide doping products are not yet approved for human use and some of them undergo preclinical or clinical trials, which complicates the study of metabolism in vivo. The investigation of the metabolism with in vitro methods is an alternative that does not require a human participation and an approval by the Ethics Committee.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioactive peptides; Doping-control; Metabolism; Proteolytic enzymes; Subcellular fractions

Mesh:

Substances:

Year:  2016        PMID: 27569051     DOI: 10.1016/j.jprot.2016.08.016

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  4 in total

1.  Genotoxicity of 12 Mycotoxins by the SOS/umu Test: Comparison of Liver and Kidney S9 Fraction.

Authors:  Maria Alonso-Jauregui; Elena González-Peñas; Adela López de Cerain; Ariane Vettorazzi
Journal:  Toxins (Basel)       Date:  2022-06-10       Impact factor: 5.075

2.  Modulation of co-stimulatory signal from CD2-CD58 proteins by a grafted peptide.

Authors:  Pravin Parajuli; Rushikesh Sable; Leeza Shrestha; Achyut Dahal; Ted Gauthier; Veena Taneja; Seetharama Jois
Journal:  Chem Biol Drug Des       Date:  2020-10-02       Impact factor: 2.817

3.  Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry.

Authors:  Sophia Krombholz; Andreas Thomas; Mario Thevis
Journal:  Metabolites       Date:  2022-02-04

4.  Effects of recombinant human growth hormone on protein malnutrition and IGF-1 and IL-2 gene expression levels in chronic nephrotic syndrome.

Authors:  Guang Dai; Donghai Wang; Hua Dong
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.